Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELOS larynx organ preservation study
2022-502751-61-00Phase 2Authorised
- Sponsor
- Leipzig University
- Start
- Nov 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, docetaxel and cisplatin in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx (2 arms), sponsored by Leipzig University. Primary endpoint: Laryngectomy-free survival. Planned start Nov 2023; status: authorised.
02
Drugs
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2022-502751-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502751-61-00.